Pharmaceutical

Ovation Science Expands Market Reach with Exclusive Canadian License Agreement

VANCOUVER, BC and LAS VEGAS, NV / ACCESSWIRE / April 11, 2024 / (CSE:OVAT)(OTCQB:OVATF) - Ovation Science Inc. ("Ovation" or…

9 months ago

Throtle’s Data Pixel Technology to Enhance HealthVerity Media Measurement and Audience Manager Solutions

HealthVerity to enhance its Media Measurement and Audience Manager solutions using Throtle's data pixel technology for precise campaign targeting and…

9 months ago

Building a Better Future: Bristol Myers Squibb 2023 ESG Report

NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company:At Bristol Myers Squibb, our vision is to…

9 months ago

Akanda Corp. Announces Closing of the Sale of RPK

London, United Kingdom--(Newsfile Corp. - April 11, 2024) - On April 1, 2024, Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the…

9 months ago

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC),…

9 months ago

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central…

9 months ago

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic…

9 months ago

SciSparc to Acquire AutoMax

TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…

9 months ago

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population…

9 months ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and…

9 months ago